TICKERNERD
Menu
CNMDCNMDHealthcare · Medical Devices

CNMD Stock Forecast: CONMED Corp. Price Predictions for 2026-2027

Last close, 21 Sept 2026
$45
−1.61% on the day

The 7 Wall Street analysts covering CONMED Corp. hold a median 12-month price target of $45 — +0.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 19 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.4B
Ticker Nerd rank
96 / 100
Median analyst target
$45
Analysts covering
7
Revenue$343.5M+0.3% y/y
Operating income$36.4M
Net income$23.1M
Free cash flow$34.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.6%
1M
−12.5%
YTD
+10.1%
1Y
−10.6%
From 52W high
−13.8%
From 52W low
+39.2%
$32
$52
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CNMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CONMED Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Issuance
94
Revisions
89
Volatility
75
Accruals
73
Quality
73
Growth
48
Momentum
48
Size
40

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (48): The shares have been drifting down relative to others.

Size (40): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CNMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$35$40$45$50Oct 25Jan 26Apr 26Jul 26CNMDHigh $49Median $45Low $43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
0 Buy6 Hold1 Sell
Low $43Median $45High $49

The green dot is the last close — the median target sits +0.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 July 2026Piper SandlerReiteratesNeutral$39 → $45
30 July 2026Wells FargoMaintainsEqual-Weight$39 → $46
9 July 2026BMO CapitalInitiatesMarket Perform—
29 June 2026B of A SecuritiesDowngradeUnderperform—
18 May 2026B of A SecuritiesMaintainsNeutral—
1 May 2026Wells FargoMaintainsEqual-Weight—
30 Apr 2026JP MorganMaintainsNeutral—
17 Mar 2026Piper SandlerDowngradeNeutral—
29 Jan 2026NeedhamReiteratesHold—
29 Jan 2026Wells FargoMaintainsEqual-Weight—
8 Dec 2025B of A SecuritiesMaintainsNeutral—
6 Nov 2025JP MorganMaintainsNeutral—
6 Nov 2025Piper SandlerMaintainsOverweight—
6 Nov 2025Wells FargoMaintainsEqual-Weight—
31 July 2025Piper SandlerMaintainsOverweight—
12 June 2025NeedhamDowngradeHold—
1 May 2025JP MorganMaintainsNeutral—
1 May 2025NeedhamMaintainsBuy—
1 May 2025Wells FargoMaintainsEqual-Weight—
28 Apr 2025StifelDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CNMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CNMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 21 Sept 2026, CONMED Corp. returned −10.6% against +15.7% for the S&P 500, dividends included.

CNMD vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26CNMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CNMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+4.0%
Analysts raising
5
Analysts cutting
0
Fundamentals

CONMED Corp. (CNMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
24.6×

Cheaper than 30% of US stocks

Price / sales
1.0×

Cheaper than 69% of US stocks

Price / book
1.3×

Cheaper than 63% of US stocks

EV / EBITDA
9.5×

Cheaper than 39% of US stocks

Growth & margins
Revenue growth (YoY)
0.3%

Higher than 28% of US stocks

Earnings growth (YoY)
7.7%

Higher than 45% of US stocks

Gross margin
57.5%

Higher than 71% of US stocks

Operating margin
14.6%

Higher than 72% of US stocks

Net margin
4.1%

Higher than 58% of US stocks

Returns & dividend
Return on equity
5.5%

Higher than 54% of US stocks

Return on assets
4.1%

Higher than 72% of US stocks

Dividend yield
1.8%

Higher than 39% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CONMED Corp. (CNMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CONMED Corp. has a market value of $1.4B and an enterprise value of $2.2B.

  • Revenue in the twelve months to 30 June 2026: $1.4B. The latest quarter grew 0.3% year on year.

  • Net income over the same four quarters: $56.5M, a 4.1% net margin.

  • Diluted earnings per share, trailing twelve months: $1.85.

  • Free cash flow in the twelve months to 30 June 2026: $134.5M.

  • CONMED Corp. spent $12.4M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 30.1M.

  • Trailing P/E: 24.6×; forward P/E: 9.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.76%, paying out 11% of earnings.

  • CONMED Corp. employs 3,900 people — $352K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Sept 2026

Data provided by Twelve Data

Peers

CNMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CNMDCONMED Corp.$1.4B
96
ATECAlphatec Holdings, Inc.$1.5B
71
IARTIntegra LifeSciences Holdings Corp.$1.2B
87
TNDMTandem Diabetes Care, Inc.$1.2B
70
BBNXBeta Bionics, Inc.$1.2B
40
AORTArtivion, Inc.$1.1B
41
PRCTPROCEPT BioRobotics Corp.$1.1B
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CONMED Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CNMD news & analysis

Harbor SMID Cap Value ETF Q2 2026 Contributors And Detractors

Seeking Alpha · 19 Sept 2026neutral

The Harbor SMID Cap Value ETF returned 22.76% in Q2 2026, outperforming its benchmark, the Russell 2500 Value Index, which returned 18.50%. Contributors to performance included Albany International and BorgWarner, which posted share gains following better-than-expected results.

Why it matters — A CNMD watcher may find this item relevant for context on the small/mid-cap value segment in which CONMED operates, though the companies specifically cited are not CNMD.

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

Zacks Investment Research · 16 Sept 2026positive

Zacks Investment Research suggests retaining CONMED stock, citing the BioBrace and AirSeal platforms, robotic growth, and easing supply bottlenecks as supporting its long-term outlook despite tariff headwinds.

Why it matters — A CNMD watcher would care because the note highlights the durable growth drivers underpinning CONMED's portfolio while acknowledging ongoing tariff-related pressures.

Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?

Zacks Investment Research · 28 Aug 2026positive

Conmed (CNMD) reported earnings 30 days ago, and its stock has risen 7.1% since that report. The article poses the question of whether this upward move can continue moving forward.

Why it matters — CNMD watchers would care because the stock's post-earnings performance may indicate how investors are reacting to the company's latest results.

CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference

Business Wire · 26 Aug 2026neutral

CONMED Corporation announced it will participate in the Wells Fargo 21st Annual Healthcare Conference, held September 8-10, 2026, in Everett, MA. Management will take part in a fireside chat on September 9th at 1:30 p.m. ET, with a live webcast available on the company's investor relations website.

Why it matters — The fireside chat gives investors an opportunity to hear directly from CONMED management about the company's outlook during a major healthcare industry conference.

CONMED Corporation: Organic Growth Is Masked By Divestitures

Seeking Alpha · 18 Aug 2026positive

CONMED reported flat headline growth of $343 million in the latest quarter, but organic growth actually increased by 6%, driven by its orthopedic surgery business. The apparent weak growth reflects the divestiture of the GI business, which the article notes masks underlying performance.

Why it matters — CNMD watchers would care because the article highlights that headline growth appears flat only due to the GI divestiture, while underlying organic growth and profitability remain stronger than the headline metrics suggest.

FAQ

Frequently asked questions about CNMD stock

What is the CNMD stock price forecast for 2026-2027?

The 7 Wall Street analysts covering CONMED Corp. have a median 12-month price target of $45, with estimates ranging from $43 to $49. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CNMD stock a buy right now?

Of the 7 analysts covering CONMED Corp., 0 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks CONMED Corp. 96 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CNMD?

As at 19 Sept 2026, CONMED Corp. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will CNMD stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +0.7% from the last close, and Ticker Nerd's factor model ranks CONMED Corp. 96 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CNMD stock forecast for 2030?

No analyst covering CONMED Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $49 over the next 12 months.

How has CNMD stock performed over the past year?

CONMED Corp. returned -10.6% over the 12 months to 21 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CONMED Corp. do?

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and equipment used in hospitals, ambulatory surgery centers, and other clinical settings. The company’s portfolio supports minimally invasive procedures across orthopedic surgery, general surgery, gynecology, thoracic surgery, and gastroenterology.

What is the latest news on CNMD?

The most recent item we track (Seeking Alpha, 19 Sept 2026): "Harbor SMID Cap Value ETF Q2 2026 Contributors And Detractors". The Harbor SMID Cap Value ETF returned 22.76% in Q2 2026, outperforming its benchmark, the Russell 2500 Value Index, which returned 18.50%. Contributors to performance included Albany International and BorgWarner, which posted share gains following better-than-expected results.

Company

About CONMED Corp.

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and equipment used in hospitals, ambulatory surgery centers, and other clinical settings. The company’s portfolio supports minimally invasive procedures across orthopedic surgery, general surgery, gynecology, thoracic surgery, and gastroenterology. Its products include surgical instruments, endoscopic technologies, electrosurgical systems, fixation devices, patient positioning solutions, and monitoring accessories designed to help healthcare professionals perform a wide range of procedures. CONMED Corporation serves medical providers in the United States and international markets, positioning itself as a specialist in operating-room technologies and procedural support tools. Based in Largo, Florida, CONMED Corporation focuses on products that are used throughout the surgical workflow, from access and visualization to treatment and patient care.

CEO Mr. Patrick J. Beyer · 3,900 employees · United States · https://www.conmed.com